Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan
Study Phase: Phase 4
Recruitment Status: Enrolling by invitation
Start Date: October 01, 2023
End Date: March 01, 2030
Inclusion Criteria:
- Referred to ECT service as a candidate for ECT treatment as assessed by treating clinician.
- Males/females 18
- 90 years of age.
- Meet DSM-5 criteria for Major Depressive Episode (MDE) as determined by Mini International Neuropsychiatric Interview (MINI PLUS 5.0.0).
- Expressing suicidal intent (thinking or behavior suggesting harming or hurting oneself with intent that death may result) or attempt (any intentional, non-fatal self-injury regardless of medical lethality, if intent to die was indicated).
- Continue to express suicidal ideation since referral as evidenced by Scale for Suicidal Ideation (SSI) ≥6)
- Meet the following criteria on symptom rating scales at screening: Hamilton Depression Scale (HAM-D 17) >15 and Montreal Cognitive Assessment (MoCA) of ≥23(to rule out baseline significant cognitive impairment)
Exclusion Criteria:
- Meeting DSM-5 criteria for schizophrenia, schizophreniform disorder, schizoaffective disorder.
- Not able to give informed consent to receive ECT or KET treatment.
- Not able to give informed consent to participate in the study.
- Meet exclusion criteria for ECT treatment as described in guidelines.
- Meet exclusion criteria for KET treatment such as:
- Pregnant or breast feeding
- Psychosis
- Severe uncontrolled medical illness
- Ketamine allergy
- Intellectual disability and unable to provide consent or follow study procedures.
-
Conditions:
- Depression